47.1 Early Pregnancy Diagnosis, Dating & Initial Complications

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications

Key Takeaways Explain This Topic AI

Qualitative urine hCG detects concentrations of 20 to 25 mIU/mL (~3 to 4 weeks after LMP), whereas quantitative serum beta-hCG in a viable intrauterine pregnancy demonstrates a minimum rise of at least 35% to 50% every 48 hours; transvaginal ultrasound (TVUS) has a discriminatory zone of 1,500 to 3,500 mIU/mL, above which an intrauterine gestational sac must be visualized.

Crown-Rump Length (CRL) measured by first-trimester transvaginal ultrasound is the single most accurate method for establishing gestational age (+/- 5 to 7 days), superseding Naegele's rule (LMP + 7 days - 3 months + 1 year) if dating discrepancy exceeds 5 days at <=8 6/7 weeks or 7 days at 9 to 13 6/7 weeks.

Ectopic pregnancy implants in the fallopian tube in >95% of cases (predominantly the ampulla); prior ectopic pregnancy is the single strongest risk factor (10% to 15% recurrence after one, >25% after two); the classic clinical triad comprises amenorrhea, abdominal/pelvic pain, and vaginal bleeding.

Single-dose intramuscular Methotrexate (50 mg/m² IM) for ectopic pregnancy requires strict eligibility: hemodynamic stability, unruptured adnexal mass <=3.5 cm, absence of embryonic cardiac activity, baseline beta-hCG <5,000 mIU/mL, normal hepatic/renal function, and confirmed compliance; monitoring mandates serum beta-hCG on Day 4 and Day 7 with a mandatory >=15% decrease between Day 4 and Day 7.

Spontaneous abortion is clinically categorized as threatened (closed os, viable fetus), inevitable (dilated os, cramping, no passage), incomplete (dilated os, partial tissue passed), complete (closed os, empty uterus), missed (closed os, retained non-viable embryo), or septic (fever, purulent discharge, uterine tenderness; mandates broad-spectrum IV antibiotics and emergent evacuation); all non-sensitized Rh(D)-negative women with early bleeding or pregnancy loss must receive Rh(D) immune globulin within 72 hours (50 mcg if <12 weeks, 300 mcg if >=12 weeks).

Last updated: September 2026

Pregnancy Diagnosis & Human Chorionic Gonadotropin (hCG) Kinetics

Confirmation of pregnancy relies on the biochemical detection of human chorionic gonadotropin (hCG), a heterodimeric glycoprotein hormone produced by embryonic syncytiotrophoblastic cells following blastocyst implantation. The hormone consists of an alpha subunit (structurally identical to luteinizing hormone [LH], follicle-stimulating hormone [FSH], and thyroid-stimulating hormone [TSH]) and a unique beta subunit (beta-hCG), which confers specific biological and immunologic activity.

Qualitative Urine hCG Testing

Sensitivity Threshold : Standard point-of-care qualitative urine tests utilize enzyme-linked immunosorbent assays (ELISA) or lateral flow immunochromatography with a detection threshold of 20 to 25 mIU/mL of beta-hCG.

Timing : Urine hCG typically turns positive approximately 8 to 10 days after conception (around 3 to 4 weeks after the Last Menstrual Period [LMP] in a standard 28-day cycle), corresponding to the first day of the missed menstrual period.

Clinical Nuances & False Results :

First Morning Void : Recommended for testing because overnight urine concentration maximizes test sensitivity. Dilute urine (specific gravity <1.005) secondary to high fluid intake can produce a false-negative result in very early gestation.

False Negatives & The "Hook Effect" : The "hook effect" (prozone phenomenon) occurs when extraordinarily high concentrations of beta-hCG (frequently seen in complete hydatidiform molar pregnancy or multiple gestations, typically >500,000 mIU/mL) oversaturate both the fixed capture antibodies and mobile tracer antibodies independently. This prevents antibody-antigen-antibody sandwich complex formation, yielding a paradoxically faint or false-negative result. When a molar pregnancy is clinically suspected but urine testing is negative or faintly positive, serial manual dilution of the urine specimen resolves the hook effect and unmasks the true positive result.

False Positives : Rare (<1%), caused by heterophile antibodies, severe proteinuria, gross hematuria, exogenous hCG administration for assisted reproduction, pituitary hCG production in perimenopausal/postmenopausal women, or hCG-secreting germ cell tumors.

Quantitative Serum Beta-hCG Dynamics

Sensitivity : Serum assays can detect beta-hCG concentrations as low as 1 to 2 mIU/mL .

Kinetics in Viable Intrauterine Pregnancy (IUP) :

In a normal, viable early gestation (<6 to 7 weeks), circulating beta-hCG concentrations increase exponentially. Although historical teaching emphasized a "doubling every 48 hours," extensive prospective clinical data define a minimum acceptable rise of 35% to 50% over 48 hours (specifically: >=49% for baseline hCG <1,500 mIU/mL; >=40% for baseline 1,500 to 3,000 mIU/mL; and >=35% for baseline >3,000 mIU/mL).

Serum beta-hCG peaks at approximately 8 to 11 weeks of gestation (reaching 100,000 to 200,000 mIU/mL) before plateauing and declining to a steady plateau of approximately 10,000 to 20,000 mIU/mL throughout the second and third trimesters.

Abnormal hCG Kinetics :

Suboptimal Rise (<35% in 48 hours) : Highly suspicious for an abnormal gestation—either an ectopic pregnancy or an impending non-viable early pregnancy loss (miscarriage).

Plateauing Levels : Characteristically seen in ectopic pregnancies where surviving extrauterine trophoblastic tissue produces a flat hCG trajectory.

Declining Levels : Indicates a non-viable pregnancy (spontaneous abortion or spontaneously resolving ectopic pregnancy).

Gestational Dating: Naegele's Rule vs. First-Trimester Ultrasound

Accurate gestational dating is paramount in obstetric care because all subsequent prenatal screenings, growth assessments, post-term inductions, and viability decisions hinge upon the established Estimated Due Date (EDD).

Naegele's Rule for Calculating EDD

Formula : EDD = First Day of LMP + 7 Days − 3 Months + 1 Year \text{EDD} = \text{First Day of LMP} + 7 \text{ Days} - 3 \text{ Months} + 1 \text{ Year} EDD = First Day of LMP + 7 Days − 3 Months + 1 Year

Physiologic Assumptions & Pitfalls :

Assumes a strictly regular 28-day menstrual cycle with ovulation and fertilization occurring precisely on Cycle Day 14 .

Inaccuracies : Naegele's rule is inherently unreliable in patients with:

• Irregular or oligomenorrheic menstrual cycles (e.g., polycystic ovary syndrome);
• Recent discontinuation of hormonal contraception within the preceding 3 months (delayed return of ovulation);
• Conception during lactational amenorrhea;

First-trimester vaginal bleeding or implantation spotting mistaken for a normal menses.

Crown-Rump Length (CRL) & Sonographic Dating Guidelines

Important

GOLD STANDARD OF GESTATIONAL DATING First-trimester transvaginal ultrasound measurement of the Crown-Rump Length (CRL) is the single most accurate method for establishing or confirming gestational age, carrying an accuracy margin of +/- 5 to 7 days . ACOG GESTATIONAL DATING DISCREPANCY RE-ASSIGNMENT THRESHOLDS

• Gestational Age at TVUS Method of Measurement Discrepancy (LMP vs. US) Action Mandated
• ═══════════════════════════════════════════════════════════════════════════════════════════════════
• <= 8 6/7 weeks Crown-Rump Length (CRL) > 5 days Change EDD to US date

9 0/7 to 13 6/7 weeks Crown-Rump Length (CRL) > 7 days Change EDD to US date

14 0/7 to 15 6/7 weeks BPD, HC, AC, FL > 7 days Change EDD to US date

16 0/7 to 21 6/7 weeks BPD, HC, AC, FL > 10 days Change EDD to US date

• >= 22 0/7 weeks BPD, HC, AC, FL > 14 to 21 days Change EDD to US date
• ═══════════════════════════════════════════════════════════════════════════════════════════════════

Clinical Rule: If the discrepancy is LESS THAN OR EQUAL TO the threshold, KEEP the LMP date!

Technique : The CRL measures the longest straight-line distance from the top of the embryonic head (crown) to the outer curvature of the breech (rump), excluding the yolk sac and fetal extremities. It is applicable up to a CRL of 84 mm (corresponding to approximately 13 6/7 weeks).

The Transvaginal Ultrasound Discriminatory Zone & Pregnancy of Unknown Location

The discriminatory zone is defined as the serum quantitative beta-hCG concentration above which a normal intrauterine gestational sac must reliably be visualized within the endometrial cavity by transvaginal ultrasound (TVUS).

Defining the Discriminatory Zone

Standard Threshold : Historically established between 1,500 and 2,000 mIU/mL (using the Third International Standard). However, current American College of Obstetricians and Gynecologists (ACOG) and Society of Radiologists in Ultrasound guidelines recommend utilizing a conservative threshold of up to 3,500 mIU/mL .

Clinical Rationale for 3,500 mIU/mL : Setting the discriminatory threshold higher prevents the catastrophic misdiagnosis of a viable, desired early intrauterine pregnancy (such as a multiple gestation or delayed conception) as an ectopic pregnancy, thereby avoiding inadvertent administration of teratogenic methotrexate or diagnostic uterine evacuation.

Sonographic Milestones of Early Intrauterine Gestation

Gestational Sac (4.5 to 5.0 weeks) : Round or oval hypoechoic fluid collection eccentrically positioned within the thickened decidua. Demonstrates the "intradecidual sign" or "double decidual sac sign" (two concentric echogenic rings surrounding the fluid collection).

Yolk Sac (5.0 to 5.5 weeks) : A round, thin-walled, hyperechoic ring within the gestational sac. The yolk sac is the first definitive sonographic confirmation of an intrauterine pregnancy , reliably distinguishing a true gestation from the central, amorphous "pseudogestational sac" (fluid/blood collection) often seen in ectopic pregnancies.

Embryo & Fetal Cardiac Motion (5.5 to 6.0 weeks) : A linear echogenic thickening adjacent to the yolk sac. Rhythmic embryonic cardiac flicker must be visualized once the CRL reaches >= 7 mm . EARLY PREGNANCY SONOGRAPHIC MILESTONES

• Gestational Age Serum beta-hCG (approx) First Visible Structure on TVUS
• ═══════════════════════════════════════════════════════════════════════════════════════════════════
• 4.5 to 5.0 Weeks 1,500 to 2,000 mIU/mL Gestational Sac (Double decidual sign)
• 5.0 to 5.5 Weeks 3,000 to 5,000 mIU/mL Yolk Sac (Confirms IUP; rules out pseudosac)
• 5.5 to 6.0 Weeks > 5,000 to 10,000 mIU/mL Embryonic Pole with Cardiac Flicker (FHR)
• ═══════════════════════════════════════════════════════════════════════════════════════════════════
• Pregnancy of Unknown Location (PUL)

Definition : A clinical scenario in which a patient has a positive qualitative urine or serum beta-hCG test, but high-resolution TVUS demonstrates neither an intrauterine pregnancy nor an extrauterine adnexal mass/ectopic gestation .

Diagnostic Management Algorithm :

If beta-hCG is <3,500 mIU/mL and patient is hemodynamically stable without peritoneal signs :

Re-evaluate serum quantitative beta-hCG in exactly 48 hours using the identical laboratory platform.

If beta-hCG rises appropriately (>=35-50%): Repeat TVUS when the discriminatory threshold (>2,000 to 3,500 mIU/mL) is achieved.

If beta-hCG plateaus or rises suboptimally (<35%): Presume non-viable pregnancy (high suspicion for ectopic pregnancy).

If beta-hCG decreases by >50%: Consistent with a spontaneously resolving failing pregnancy (early miscarriage or resolving ectopic); track serial hCG weekly to <5 mIU/mL.

If beta-hCG is >=3,500 mIU/mL and the uterine cavity is completely empty :

Highly indicative of an ectopic pregnancy (or a completely expelled miscarriage). Proceed immediately with targeted ectopic evaluation and intervention.

Ectopic Pregnancy: Anatomy, Epidemiology & Risk Stratification

An ectopic pregnancy occurs when a fertilized blastocyst implants outside the functional endometrium of the uterine cavity. Ectopic pregnancy accounts for 1% to 2% of all pregnancies in the United States but remains the leading cause of first-trimester pregnancy-related maternal mortality , primarily due to catastrophic intra-abdominal hemorrhage.

Anatomical Distribution of Ectopic Implantation

Fallopian Tube (>95% of cases) :

Ampulla : 70% to 80% (most common location due to widest luminal caliber and site of fertilization).

Isthmus : 12% (narrow lumen, prone to early rupture at 6 to 8 weeks).

Fimbriae (infundibulum) : 5% to 10% .

Interstitial / Cornual : 2% to 3% .

Clinical Critical Pearl : Interstitial pregnancies implant in the intramural segment of the fallopian tube surrounded by myometrium. Because the myometrium can stretch, these pregnancies often remain unruptured until 8 to 16 weeks of gestation . When rupture eventually occurs, proximity to the ascending uterine artery branches produces sudden, massive, and rapidly fatal cataclysmic hemorrhage.

Non-Tubal Sites (<5% of cases) :

• Ovarian (3%);
• Cesarean scar defect (isthmocele; 1% to 2%);
• Cervical (1%);

Abdominal cavity (1%).

Major Risk Factors RISK STRATIFICATION FOR ECTOPIC PREGNANCY

• Risk Category Risk Factor Relative Risk / Odds Ratio
• ═══════════════════════════════════════════════════════════════════════════════════════════════════
• HIGH RISK Prior Ectopic Pregnancy (STRONGEST FACTOR) Recurrence OR: 3.0 to 13.0
• (10-15% after 1 ectopic; >25% after >=2)
• Prior Fallopian Tube Surgery / Tubal Ligation OR: 9.0 to 21.0
• Documented Tubal Pathology / Hydrosalpinx OR: 3.5 to 4.0
• In Situ Intrauterine Device (IUD)* OR: 4.5 to 10.0

• MODERATE RISK History of Pelvic Inflammatory Disease (PID) OR: 2.5 to 3.5
• History of Infertility / Assisted Reproduction OR: 2.5 to 3.0
• Multiple Sexual Partners / STIs (Chlamydia) OR: 2.0 to 3.0

• MILD / OTHER Cigarette Smoking (>20 cigarettes/day) OR: 1.5 to 2.5
• Previous Pelvic / Abdominal Surgery OR: 1.5 to 2.0
• ═══════════════════════════════════════════════════════════════════════════════════════════════════
• *Note on IUDs: IUDs are highly effective contraceptives that dramatically lower the overall
• absolute rate of pregnancy. However, if an accidental conception occurs with an IUD in situ,

up to 30% to 50% of those pregnancies are ectopic!

• The Cardinal Clinical Triad
• Amenorrhea or Delayed Menses (frequently with a history of missed period 6 to 8 weeks prior);
• Abdominal / Pelvic Pain (present in >95% of symptomatic cases; typically unilateral, sharp, or dull ache);

Vaginal Bleeding or Spotting (present in 60% to 80%; typically dark brown or intermittent due to sloughing of decidualized endometrium from inadequate hCG support).

Clinical Presentation of Tubal Rupture

Tubal rupture represents a surgical catastrophe characterized by:

Sudden, tearing, excruciating lower abdominal and pelvic pain;

Kehr Sign : Referred sharp pain to the ipsilateral shoulder tip caused by subdiaphragmatic blood collection irritating the phrenic nerve (C3-C5 distribution);

Peritoneal irritation: Involuntary guarding, rebound tenderness, and marked abdominal rigidity;

Hemodynamic shock: Hypotension, narrow pulse pressure, tachycardia, diaphoresis, syncope, or altered mental status.

Medical vs. Surgical Management of Ectopic Pregnancy

Once an ectopic pregnancy is identified, management involves medical therapy with methotrexate or surgical intervention via laparoscopy or laparotomy.

Medical Therapy: Methotrexate (MTX)

Methotrexate is a structural folate analogue that competitively inhibits dihydrofolate reductase (DHFR) , preventing the conversion of dihydrofolate to tetrahydrofolate. This disrupts purine and thymidylate nucleotide synthesis, arresting DNA replication, RNA synthesis, and cell proliferation in rapidly dividing trophoblastic tissues. METHOTREXATE CANDIDACY & SELECTION CRITERIA

• Strict Eligibility Criteria (ALL MUST BE MET) Absolute Contraindications
• ═══════════════════════════════════════════════════════════════════════════════════════════════════
• 1. Hemodynamically stable; no active hemorrhage • Hemodynamic instability / ruptured tubal mass
• 2. Unruptured adnexal mass <= 3.5 cm diameter • Positive embryonic cardiac activity on TVUS
• 3. Absence of embryonic cardiac motion on TVUS • Baseline serum beta-hCG > 5,000 mIU/mL (relative)
• 4. Baseline serum beta-hCG < 5,000 mIU/mL • Intrauterine pregnancy (desired or unexcluded)
• 5. Normal renal function (creatinine, BUN) • Renal insufficiency (serum Cr > 1.3 mg/dL)
• 6. Normal hepatic enzymes (AST, ALT < 2x ULN) • Active liver disease or chronic alcoholism
• 7. Normal baseline hematology (no leukopenia/thromb) • Immunodeficiency / active pulmonary disease
• 8. Patient willing and able to comply with follow-up • Breastfeeding; allergy/hypersensitivity to MTX
• ═══════════════════════════════════════════════════════════════════════════════════════════════════
• Methotrexate Dosing & The Single-Dose Protocol

Dosage : 50 mg/m² body surface area (BSA) administered intramuscularly (IM) as a single dose.

Required Baseline Labs : Quantitative beta-hCG, Type and Screen (with Rh status), Complete Blood Count (CBC), Comprehensive Metabolic Panel (hepatic transaminases, BUN, creatinine). METHOTREXATE SINGLE-DOSE PROTOCOL MONITORING TIMELINE

• Protocol Day Action / Laboratory Test Expected Pattern & Clinical Decision
• ═══════════════════════════════════════════════════════════════════════════════════════════════════

Day 1 Administer Methotrexate 50 mg/m² IM Establish baseline quantitative beta-hCG.

Day 4 Measure serum quantitative beta-hCG beta-hCG commonly INCREASES or plateaus

due to trophoblast lysis. Do not panic!

Day 7 Measure serum quantitative beta-hCG MANDATORY CRITERION: beta-hCG must

DECREASE BY >= 15% from Day 4 to Day 7.

Post-Day 7 Weekly serum quantitative beta-hCG If >=15% drop achieved: track weekly until

completely undetectable (<5 mIU/mL).

If <15% drop: give 2nd MTX dose (50 mg/m²)

on Day 7 OR proceed to surgical exploration.

═══════════════════════════════════════════════════════════════════════════════════════════════════

Patient Counseling During MTX Therapy :

Discontinue all folic acid-containing supplements and prenatal vitamins (folate directly overcomes MTX enzyme inhibition);

Avoid NSAIDs (aspirin, ibuprofen, naproxen), as NSAIDs decrease renal blood flow and competitive tubular clearance of MTX, increasing toxic drug exposure;

Avoid alcohol (hepatotoxicity risk);

Avoid vigorous physical exercise, heavy lifting, and sexual intercourse until hCG clears (reduces risk of mechanical rupture of the weakened fallopian tube);

Avoid prolonged direct sunlight exposure (photosensitivity dermatologic reaction);

"Separation Pain" : 50% of patients experience transient, mild-to-moderate lower quadrant abdominal cramping between Days 2 and 5 post-injection secondary to tubal abortion and hematoma formation. It must be differentiated from true tubal rupture (rupture is accompanied by peritoneal signs, syncope, tachycardia, or severe hypotension).

Surgical Management

Indications : Hemodynamic instability, suspected or confirmed tubal rupture, peritoneal signs, adnexal mass >3.5 cm, visible embryonic cardiac activity on ultrasound, initial serum beta-hCG >=5,000 mIU/mL, contraindications to methotrexate, or failed medical management.

Surgical Approaches :

Laparoscopic Salpingectomy : Complete resection of the affected fallopian tube. Preferred procedure in cases of extensive tubal destruction, recurrent ectopic pregnancy in the same tube, completed childbearing, or uncontrolled hemorrhage.

Laparoscopic Salpingostomy : Linear longitudinal incision along the antimesenteric border of the fallopian tube over the ectopic implantation, evacuation of the products of conception, and preservation of the tube (heals by secondary intention). Indicated in patients desiring future fertility who possess a compromised or absent contralateral fallopian tube. Requires postoperative weekly beta-hCG monitoring until zero to rule out persistent trophoblastic tissue (occurs in 5-10% of salpingostomies; treated with a single dose of prophylactic MTX).

Emergent Exploratory Laparotomy : Indicated in patients presenting in profound, uncorrectable hemorrhagic shock with massive hemoperitoneum.

The Spontaneous Abortion (Miscarriage) Spectrum

Early pregnancy loss is defined as the spontaneous demise of an intrauterine pregnancy prior to 20 0/7 weeks of gestation . Approximately 10% to 20% of clinically recognized pregnancies end in spontaneous abortion, with >80% occurring during the first 12 weeks (first trimester). Sporadic chromosomal anomalies—predominantly autosomal trisomies (trisomy 16 being the most common, followed by trisomies 22 and 21), polyploidy, and monosomy X (45,X)—account for >50% of first-trimester losses. THE CLINICAL SPECTRUM OF SPONTANEOUS ABORTION

• Classification Cervical Os Vaginal Bleeding Uterine Cramping Ultrasound Findings / POC
• ════════════════════════════════════════════════════════════════════════════════════════════════════
• Threatened CLOSED Present (Light to Mild or Absent Viable embryo with
• Abortion Moderate) detectable cardiac activity

• Inevitable DILATED / Present (Moderate Moderate to Non-viable gestation or active
• Abortion OPEN to Heavy) Severe membrane rupture; no POC passed

• Incomplete DILATED / Present (Heavy, Severe Heterogeneous retained POC
• Abortion OPEN with tissue passage) present within endometrial cavity

• Complete CLOSED Decreasing / Subsided / Empty uterus; regular, thin
• Abortion Minimal Minimal endometrial stripe (<5-10 mm)

• Missed CLOSED Absent or Absent or Retained non-viable embryo;
• Abortion Minimal Spotting Minimal no fetal heart tone (FHT)

• Septic OPEN or Purulent, Foul Severe Pelvic Retained POC or endometritis;
• Abortion CLOSED Discharge Cramping/Tenderness uterine tenderness, fever, chills
• ════════════════════════════════════════════════════════════════════════════════════════════════════
• Strict Sonographic Diagnostic Criteria for Pregnancy Failure

According to the American College of Obstetricians and Gynecologists (ACOG) and Society of Radiologists in Ultrasound guidelines, early pregnancy loss is definitively diagnosed when TVUS demonstrates:

• Crown-Rump Length (CRL) >= 7 mm without visible embryonic cardiac motion ;
• Mean Sac Diameter (MSD) >= 25 mm without an identifiable embryo ;

Absence of an embryo with a heartbeat >= 14 days after an initial scan demonstrating a gestational sac without a yolk sac;

Absence of an embryo with a heartbeat >= 11 days after an initial scan demonstrating a gestational sac with a yolk sac.

Clinical Management of Early Pregnancy Loss

For patients with confirmed, non-viable first-trimester early pregnancy loss (incomplete, complete, or missed abortion) who are clinically stable without infection, three management strategies are available: expectant, medical, and surgical.

1. Expectant Management

Mechanism : Allowing spontaneous uterine contractions to naturally expel the retained gestational tissue.

Suitability : Most successful in first-trimester incomplete abortion (success rate >70% to 80% within 1 to 2 weeks); significantly lower success rate in missed abortion (<50%). Limited to stable patients with gestation <10 to 12 weeks.

Duration : Typically observed for up to 14 to 28 days . If spontaneous expulsion does not occur within this window or if excessive hemorrhage develops, active medical or surgical management is initiated.

2. Medical Management

The Evidence-Based Combination Regimen :

Mifepristone 200 mg orally in a single dose , followed 24 hours later by Misoprostol 800 mcg buccally (or vaginally) .

Mechanism : Mifepristone is a synthetic 19-norsteroid that competitively antagonizes the progesterone receptor, causing decidual necrosis, cervical softening, and sensitization of the myometrium to prostaglandin stimulation. Misoprostol is a synthetic prostaglandin E1 (PGE1) analogue that induces strong myometrial contractions and cervical dilation.

Superiority : The landmark Mifepristone Pretreatment Trial (ACOG practice bulletin) demonstrated that pretreatment with oral mifepristone prior to misoprostol achieves complete pregnancy expulsion in 84% to 91% of patients, compared to only 67% with misoprostol monotherapy alone.

Patient Counseling & Anticipatory Guidance :

Cramping and heavy bleeding typically begin within 2 to 4 hours after misoprostol administration, peaking during tissue expulsion.

Prescribe scheduled NSAIDs (ibuprofen 600-800 mg PO q8h) and provide rescue oral opioids (oxycodone/acetaminophen) for severe cramping.

Red Flag Return Precautions : Immediate emergency evaluation is required if the patient soaks through >= 2 full-sized maxi pads per hour for 2 consecutive hours , passes blood clots larger than a lemon, develops fever >38.0°C (>100.4°F), or experiences severe pelvic pain unresponsive to analgesics.

3. Surgical Management

Techniques : Manual Vacuum Aspiration (MVA) in the outpatient clinic setting under local paracervical block, or Electric Suction Curettage in the operating suite.

Absolute Indications : Hemodynamic instability, active uncontrolled uterine hemorrhage, suspected septic abortion, concurrent severe medical comorbidities (severe coagulopathy, cardiovascular disease), or patient preference for immediate, definitive resolution.

Advantage : Achieves >98% to 99% immediate complete clearance without prolonged bleeding.

4. Septic Abortion Emergency Management

Caution

SEPTIC ABORTION IS A LIFE-THREATENING EMERGENCY Septic abortion arises from polymicrobial ascending intrauterine infection of retained necrotic products of conception, often involving coliforms, group B streptococci, anaerobes ( Bacteroides , Peptostreptococcus ), and rarely Clostridium perfringens .

Clinical presentation features high fevers, chills, profuse malodorous or purulent cervical discharge, extreme uterine and cervical motion tenderness, and rapid evolution into septic shock and disseminated intravascular coagulation (DIC).

Emergency Protocol :

• Obtain immediate blood cultures (2 sets) and cervical cultures;
• Initiate immediate aggressive intravenous crystalloid resuscitation;

Administer immediate broad-spectrum intravenous triple antibiotics :

Ampicillin 2 g IV every 6 hours PLUS Gentamicin 5 mg/kg IV daily PLUS Clindamycin 900 mg IV every 8 hours (or Metronidazole 500 mg IV q8h);

Alternative : Ampicillin-Sulbactam 3 g IV q6h OR Piperacillin-Tazobactam 3.375-4.5 g IV q6h;

Perform Emergent Surgical Uterine Evacuation (Suction D&C) : Uterine evacuation must never be delayed waiting for antibiotics to "take effect." The infected, necrotic intrauterine nidus must be removed within 2 to 4 hours of antibiotic initiation to arrest the source of endotoxin release.

Rh(D) Alloimmunization Prophylaxis in Early Pregnancy Loss

Fetomaternal hemorrhage can occur during any first-trimester bleeding episode, spontaneous abortion, induced termination, ectopic pregnancy, or uterine instrumental evacuation. If an Rh(D)-negative, non-sensitized mother is exposed to Rh(D)-positive fetal erythrocytes, her immune system produces anti-D immunoglobulins (alloimmunization). In subsequent pregnancies, maternal anti-D IgG antibodies readily cross the placenta, bind fetal red blood cells, and trigger life-threatening hemolytic disease of the fetus and newborn (HDFN), erythroblastosis fetalis, and hydrops fetalis. RH(D) IMMUNE GLOBULIN (RHOGAM) DOSING PROTOCOL

• Gestational Age at Event Recommended Dose of Rh(D) Immune Globulin Timing of Administration
• ═══════════════════════════════════════════════════════════════════════════════════════════════════════
• < 12 0/7 Weeks Gestation 50 mcg (Microdose) Intramuscularly* Within 72 HOURS of event

• >= 12 0/7 Weeks Gestation 300 mcg (Standard Dose) Intramuscularly Within 72 HOURS of event
• ═══════════════════════════════════════════════════════════════════════════════════════════════════════
• *Note: If the 50 mcg microdose formulation is not immediately available, the standard 300 mcg

vial can be administered safely at any gestational age without adverse effects.

Clinical Execution Mandates

Window of Administration : Rh(D) immune globulin must be administered within 72 hours of the onset of vaginal bleeding or operative uterine intervention.

Late Administration : If the 72-hour window has lapsed, the dose should still be administered as soon as recognized up to 28 days post-exposure , as partial protection may still be conferred.

Who Requires Rh(D) Prophylaxis? : All pregnant women who are Rh(D)-negative and have a negative indirect Coombs test (unsensitized) presenting with:

• First-trimester vaginal bleeding (threatened abortion);
• Confirmed spontaneous abortion (incomplete, complete, missed);
• Ectopic pregnancy (medical or surgical management);
• Induced abortion (medical or aspiration);

Transchorionic procedures (chorionic villus sampling) or abdominal trauma.

Loading diagram... Clinical Diagnostic & Management Triage for First-Trimester Vaginal Bleeding and Pelvic Pain